ArticleJournal of gastrointestinal oncology2026
Comparison of preoperative urinary Titin levels and serum Titin levels in patients with gastrointestinal malignancy.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, reports using urinary Titin (U-Titin) levels to evaluate patients with muscular dystrophy, myocardial infarction, myasthenia gravis, gastrointestinal malignancy (GIM), chronic liver disease, and sarcopenia have been sporadically observed; however, reports using serum Titin (S-Titin) levels are scarce. We report here on the measurement of S-Titin, which has now become feasible. Methods: This study included 104 patients who underwent surgery for the diagnosis of GIM in our department between May 2024 and November 2025. Preoperative S-Titin and U-Titin levels were measured to investigate their correlation. Furthermore, using InBody, we measured skeletal muscle mass index (SMI), percent body fat (PBF), fat mass index (FMI), extracellular water (ECW)/total body water (TBW) and whole-body phase angle (Ph A) to investigate the relationship with S-Titin and U-Titin. Results: There were 28 female and 76 male patients, with a median age of 68 (range, 54-89) years. Location of malignant diseases was as follows: 42 cases of hepatobiliary-pancreatic cancer, 36 cases of colorectal cancer, and 26 cases of upper gastrointestinal cancer. S-Titin and U-Titin levels showed a strong positive correlation (r=0.78, y=0.19x+1.40, P<0.001). PBF, FMI, and Ph A showed a weak negative correlation with both levels, while ECW/TBW showed a weak positive correlation, however, no correlation was observed with SMI. Conclusions: This study suggests that S-Titin levels, like U-Titin levels, may serve as a potential biomarker for skeletal muscle and nutritional disorders in GIM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.